Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: A mechanistic study using heart rate variability as a pharmacodynamic measure

Jill C. Chappell, Richard Kovacs, Harry Haber, Ryan Wright, Malcolm I. Mitchell, Michael Detke, Beth Pangallo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A decrease in heart rate variability (HRV) can indicate increased sympathetic nervous system activity and possibly increased norepinephrine levels. In this randomized, placebo-and escitalopram (ESC)-controlled, subject-blind, 2-period, crossover study, 26 healthy subjects 50 to 65 years old received duloxetine (DLX) 60 mg once daily or ESC 20 mg once daily for 11 days, each in sequential study periods separated by a 10-day or more washout period. Continuous electrocardiogram recordings were obtained by Holter monitoring (baseline, day 9, and day 10 of treatment). Duloxetine and ESC did not produce any clinically significant effects on standard measures of HRV, which included SD of normal R-R intervals and the root mean square difference among successive R-R normal intervals index values, mean change in SD of normal R-R intervals, and frequency domain analysis. However, treatment with DLX was associated with significantly less change from baseline in total beats per 24 hours than ESC, which was an unexpected finding compared with previous observations in which vital signs were measured at a specific time point while awake. In conclusion, in healthy adults exposed to DLX or ESC, no clinically significant effects on HRV were observed.

Original languageEnglish
Pages (from-to)236-239
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume33
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Citalopram
Heart Rate
Ambulatory Electrocardiography
Vital Signs
Sympathetic Nervous System
Cross-Over Studies
Norepinephrine
Healthy Volunteers
Electrocardiography
Placebos
Duloxetine Hydrochloride
Therapeutics

Keywords

  • duloxetine
  • escitalopram
  • heart rate variability
  • norepinephrine
  • standard deviation of normal R-R intervals

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability : A mechanistic study using heart rate variability as a pharmacodynamic measure. / Chappell, Jill C.; Kovacs, Richard; Haber, Harry; Wright, Ryan; Mitchell, Malcolm I.; Detke, Michael; Pangallo, Beth.

In: Journal of Clinical Psychopharmacology, Vol. 33, No. 2, 04.2013, p. 236-239.

Research output: Contribution to journalArticle

Chappell, Jill C. ; Kovacs, Richard ; Haber, Harry ; Wright, Ryan ; Mitchell, Malcolm I. ; Detke, Michael ; Pangallo, Beth. / Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability : A mechanistic study using heart rate variability as a pharmacodynamic measure. In: Journal of Clinical Psychopharmacology. 2013 ; Vol. 33, No. 2. pp. 236-239.
@article{02e7a4092b6640d593671ea99ba3538c,
title = "Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: A mechanistic study using heart rate variability as a pharmacodynamic measure",
abstract = "A decrease in heart rate variability (HRV) can indicate increased sympathetic nervous system activity and possibly increased norepinephrine levels. In this randomized, placebo-and escitalopram (ESC)-controlled, subject-blind, 2-period, crossover study, 26 healthy subjects 50 to 65 years old received duloxetine (DLX) 60 mg once daily or ESC 20 mg once daily for 11 days, each in sequential study periods separated by a 10-day or more washout period. Continuous electrocardiogram recordings were obtained by Holter monitoring (baseline, day 9, and day 10 of treatment). Duloxetine and ESC did not produce any clinically significant effects on standard measures of HRV, which included SD of normal R-R intervals and the root mean square difference among successive R-R normal intervals index values, mean change in SD of normal R-R intervals, and frequency domain analysis. However, treatment with DLX was associated with significantly less change from baseline in total beats per 24 hours than ESC, which was an unexpected finding compared with previous observations in which vital signs were measured at a specific time point while awake. In conclusion, in healthy adults exposed to DLX or ESC, no clinically significant effects on HRV were observed.",
keywords = "duloxetine, escitalopram, heart rate variability, norepinephrine, standard deviation of normal R-R intervals",
author = "Chappell, {Jill C.} and Richard Kovacs and Harry Haber and Ryan Wright and Mitchell, {Malcolm I.} and Michael Detke and Beth Pangallo",
year = "2013",
month = "4",
doi = "10.1097/JCP.0b013e31828567b6",
language = "English",
volume = "33",
pages = "236--239",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability

T2 - A mechanistic study using heart rate variability as a pharmacodynamic measure

AU - Chappell, Jill C.

AU - Kovacs, Richard

AU - Haber, Harry

AU - Wright, Ryan

AU - Mitchell, Malcolm I.

AU - Detke, Michael

AU - Pangallo, Beth

PY - 2013/4

Y1 - 2013/4

N2 - A decrease in heart rate variability (HRV) can indicate increased sympathetic nervous system activity and possibly increased norepinephrine levels. In this randomized, placebo-and escitalopram (ESC)-controlled, subject-blind, 2-period, crossover study, 26 healthy subjects 50 to 65 years old received duloxetine (DLX) 60 mg once daily or ESC 20 mg once daily for 11 days, each in sequential study periods separated by a 10-day or more washout period. Continuous electrocardiogram recordings were obtained by Holter monitoring (baseline, day 9, and day 10 of treatment). Duloxetine and ESC did not produce any clinically significant effects on standard measures of HRV, which included SD of normal R-R intervals and the root mean square difference among successive R-R normal intervals index values, mean change in SD of normal R-R intervals, and frequency domain analysis. However, treatment with DLX was associated with significantly less change from baseline in total beats per 24 hours than ESC, which was an unexpected finding compared with previous observations in which vital signs were measured at a specific time point while awake. In conclusion, in healthy adults exposed to DLX or ESC, no clinically significant effects on HRV were observed.

AB - A decrease in heart rate variability (HRV) can indicate increased sympathetic nervous system activity and possibly increased norepinephrine levels. In this randomized, placebo-and escitalopram (ESC)-controlled, subject-blind, 2-period, crossover study, 26 healthy subjects 50 to 65 years old received duloxetine (DLX) 60 mg once daily or ESC 20 mg once daily for 11 days, each in sequential study periods separated by a 10-day or more washout period. Continuous electrocardiogram recordings were obtained by Holter monitoring (baseline, day 9, and day 10 of treatment). Duloxetine and ESC did not produce any clinically significant effects on standard measures of HRV, which included SD of normal R-R intervals and the root mean square difference among successive R-R normal intervals index values, mean change in SD of normal R-R intervals, and frequency domain analysis. However, treatment with DLX was associated with significantly less change from baseline in total beats per 24 hours than ESC, which was an unexpected finding compared with previous observations in which vital signs were measured at a specific time point while awake. In conclusion, in healthy adults exposed to DLX or ESC, no clinically significant effects on HRV were observed.

KW - duloxetine

KW - escitalopram

KW - heart rate variability

KW - norepinephrine

KW - standard deviation of normal R-R intervals

UR - http://www.scopus.com/inward/record.url?scp=84874934620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874934620&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e31828567b6

DO - 10.1097/JCP.0b013e31828567b6

M3 - Article

C2 - 23422380

AN - SCOPUS:84874934620

VL - 33

SP - 236

EP - 239

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -